1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Malignant Pleural Effusion Global Clinical Trials Review, H2, 2016

Malignant Pleural Effusion Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Malignant Pleural Effusion Global Clinical Trials Review, H2, 2016" provides an overview of Malignant Pleural Effusion clinical trials scenario. This report provides top line data relating to the clinical trials on Malignant Pleural Effusion. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Malignant Pleural Effusion Global Clinical Trials Review, H2, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Malignant Pleural Effusion to Respiratory Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Malignant Pleural Effusion to Respiratory Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Malignant Pleural Effusion Therapeutics Clinical Trials 27
Prominent Drugs 28
Clinical Trial Profile Snapshots 29
Appendix 85
Abbreviations 85
Definitions 85
Research Methodology 86
Secondary Research 86
About GlobalData 87
Contact Us 87
Disclaimer 87
Source 88

List of Tables
Malignant Pleural Effusion Therapeutics, Global, Clinical Trials by Region, 2016* 6
Malignant Pleural Effusion Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Malignant Pleural Effusion Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Malignant Pleural Effusion Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Malignant Pleural Effusion Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Malignant Pleural Effusion Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Malignant Pleural Effusion Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Malignant Pleural Effusion Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Malignant Pleural Effusion to Respiratory Clinical Trials, G7 Countries (%), 2016* 14
Malignant Pleural Effusion Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Malignant Pleural Effusion Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Malignant Pleural Effusion to Respiratory Clinical Trials, E7 Countries (%), 2016* 17
Malignant Pleural Effusion Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Malignant Pleural Effusion Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Malignant Pleural Effusion Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Malignant Pleural Effusion Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Malignant Pleural Effusion Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Malignant Pleural Effusion Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Malignant Pleural Effusion Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Malignant Pleural Effusion Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Malignant Pleural Effusion Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Malignant Pleural Effusion Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Malignant Pleural Effusion Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List of Figures
Malignant Pleural Effusion Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Malignant Pleural Effusion Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Malignant Pleural Effusion Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Malignant Pleural Effusion Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Malignant Pleural Effusion Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Malignant Pleural Effusion Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Malignant Pleural Effusion Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
Proportion of Malignant Pleural Effusion to Respiratory Clinical Trials, G7 Countries (%), 2016* 14
Malignant Pleural Effusion Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Malignant Pleural Effusion Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Malignant Pleural Effusion to Respiratory Clinical Trials, E7 Countries (%), 2016* 17
Malignant Pleural Effusion Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Malignant Pleural Effusion Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Malignant Pleural Effusion Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Malignant Pleural Effusion Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Malignant Pleural Effusion Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Malignant Pleural Effusion Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Malignant Pleural Effusion Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Malignant Pleural Effusion Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Malignant Pleural Effusion Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Malignant Pleural Effusion Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Malignant Pleural Effusion Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 86

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.